Compare YETI & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YETI | LIVN |
|---|---|---|
| Founded | 2006 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | 2018 | 1993 |
| Metric | YETI | LIVN |
|---|---|---|
| Price | $47.53 | $63.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | $41.92 | ★ $67.38 |
| AVG Volume (30 Days) | ★ 1.6M | 512.1K |
| Earning Date | 02-12-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.93 | N/A |
| Revenue | ★ $1,831,326,000.00 | $1,348,962,000.00 |
| Revenue This Year | $4.00 | $12.25 |
| Revenue Next Year | $5.47 | $6.68 |
| P/E Ratio | $24.63 | ★ N/A |
| Revenue Growth | 1.56 | ★ 8.63 |
| 52 Week Low | $26.61 | $32.48 |
| 52 Week High | $51.29 | $65.57 |
| Indicator | YETI | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 53.84 | 53.01 |
| Support Level | $47.84 | $60.79 |
| Resistance Level | $49.76 | $64.78 |
| Average True Range (ATR) | 1.76 | 1.64 |
| MACD | -0.27 | -0.10 |
| Stochastic Oscillator | 41.33 | 54.91 |
YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.